Search Results for: Gamida cell

Success in Sickle-Cell Disease trial

Israeli biotech Gamida Cell published positive results in its Phase I/II trial of NiCord, for the treatment of Sickle-Cell Disease (SCD). All the patients that completed the trial were free of SCD symptoms. http://www.globes.co.il/en/article-gamida-reports-positive-nicord-results-1001165382

Posted in Israel's Medical Achievements | Leave a comment

Treatment for Sickle Cell Disease

The first patient with Sickle Cell Disease (SCD) has received a transplant of CordIn from Israeli biotech Gamida Cell.  CordIn is an alternative for patients awaiting a suitable match for bone marrow transplants.  Trials of CordIn are planned for patients … Continue reading

Posted in Israel's Medical Achievements | Leave a comment

Success in trials of stem cells for blood cancer

(Thanks to Atid-EDI) Early trials of NiCord (umbilical cord stem cells) from Israel’s Gamida Cell have proved successful in maintaining the health of patients with high-risk hematological malignancies. The treatment was safe and reduced the time to recovery period. http://www.gamida-cell.com/press_item.asp?ID=54

Posted in Israel's Medical Achievements | Leave a comment

Israeli stem cells slow down blood cancer

Israel’s Gamida Cell Ltd. reported success in the Phase III clinical trial of its StemEx treatment for leukemia and lymphoma. Compared to a control group, far more patients receiving StemEx survived 100 days or more following transplantation. http://www.gamida-cell.com/press_item.asp?ID=53

Posted in Israel's Medical Achievements | Leave a comment

More approvals on the way

This article identifies three more Israeli companies that are expected to receive FDA approval for treatments in 2023. They are Gamida Cell (Omidubicel / NiCord – bone marrow transplants); Protalix (PRX-102 – Fabry disease); and BioLineRX (BL-8040 / Motixafortide – … Continue reading

Posted in Israel's Medical Achievements | Leave a comment

Investment in Israeli startups 28/2/21

CYE raised $120 million; Gamida Cell raised $75 million; Personetics raised $75 million; Pliops raised $65 million; PerimeterX raised $57 million; Lusha raised $40 million; Redefine Meat raised $29 million; Atera raised $25 million; Nanit raised $25 million; EquityBee raised … Continue reading

Posted in Economy & Business | Leave a comment

Blood cancer treatment trial succeeds

Israel’s Gamida Cell (reported here previously) published the results of its Phase 3 trial of omidubicel (previously NiCord) in blood-based cancer patients. The treatment resulted in faster blood count recovery, fewer bacterial and viral infections, and fewer days in the … Continue reading

Posted in Israel's Medical Achievements | Leave a comment

Good news for bone-marrow transplants

Israeli biotech Gamida Cell (see here) published positive results in its Phase 3, 50-center trial of NiCord (now called Omidubicel) that aims to increase the success of bone marrow transplants in blood cancer patients. The stem cells were established much … Continue reading

Posted in Israel's Medical Achievements | Leave a comment

Blood cancer treatment success

Israel’s Gamida Cell reported good results from Duke University trials of its NiCord blood cancer treatment.  Compared with 101 patients receiving ordinary umbilical cord blood, the 18 patients using NiCord had a lower mortality rate, less infections and less time … Continue reading

Posted in Israel's Medical Achievements | Leave a comment

Global demand for Israeli health tech

Multinationals have recently been investing heavily in Israeli life science companies. They include Boston Scientific into MValve (heart valves), Novartis into Gamida Cell (stem cell therapies) and eHealthVentures into Intendu (brain dysfunction treatment). http://www.starterincubator.com/venture-capital/israeli-health-tech-is-heating-up-with-a-wave-of-interest-from-abroad/

Posted in Economy & Business | Leave a comment